Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announced a partnership with Harrow, a leading North American eyecare company, to launch an authorized generic of Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension), which treats and relieves bacterial eye infections.
Maxitrol and generic equivalents had annual sales of $20.8 million in the U.S., according to IQVIA data, as of January 2025.
"Today marks the culmination of months of work to bring this exciting new authorized generic to the marketplace. This product is a great addition to our generic portfolio, providing patients another affordable prescription option," said Thomas Sammler, VP Commercial Operations.
For more information about Nordic Pharma, Inc. visit www.nordicpharmausa.com.
About Nordic Group B.V.
Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products.
Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women's Health. Nordic Group has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide.
Nordic Group is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.
About Nordic Pharma, Inc.
Nordic Pharma, Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
About Harrow
Harrow, Inc. is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.